Citizens JMP raised the firm’s price target on Privia Health (PRVA) to $29 from $26 and keeps an Outperform rating on the shares. Privia Health’s key operating and financial metrics for Q4 beat the firm’s projections, the analyst tells investors in a research note. The firm views recent actions by other value-based care entities to implement a more measured philosophy toward risk, together with Privia’s consistent execution, as further validation of Privia’s approach.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Group: Strong Financial Performance and Strategic Positioning Justify Buy Rating and Increased Price Target
- Privia Health price target raised to $40 from $25 at Piper Sandler
- Privia Health price target raised to $30 from $29 at Canaccord
- Privia Health Group’s Strong Performance and Promising Outlook Justifies Buy Rating
- Privia Health Group Reports Strong 2024 Financial Results